

Wellnex Life Limited (ASX:WNX)

Completion of Placement to strategic investor at \$1.40 per share

Investment Highlights

- Wellnex Life has completed a placement to strategic investor at a 133% premium to the current share price at \$1.40 per share
- Placement validated the future plans of the business and growth opportunities of
- Wellnex Life experiencing significant growth across all business units in FY25 primarily in the high value brand business
- Wellnex Life expects to continue to see substantial growth for the remainder of FY25.

Wellnex Life Limited (ASX) ("Wellnex Life" or the "Company"), is pleased to announce that it has finalised a placement of \$500,000 with a strategic investor at a 133% premium to the current share price at \$1.40 per share (\$0.605 – closing price 18 November 2024). The placement at a substantial premium validates the future business plans and growth opportunities of the Company with a strong pipeline of growth levers for the remainder of FY25 and beyond.

Wellnex Life is seeing significant growth across all of its business units in FY25, especially in the high margin and value brands that have experienced a 128% growth compared to the same period in FY24 (PCP). Sales for the first 4 months of FY25 was \$5.05 million compared to \$2.1 million for the same period in FY24.

IP licensing, with the imminent launch in the UK with Haleon, will experience significant increase in sales in FY25 with the first 4 months of FY25 up 27% compared to the whole of FY24. Total revenue and purchase orders received so far in FY25 was \$5.5 million, compared to \$4.3 million for the whole of FY24.

This ASX announcement has been authorised by the Board of Wellnex Life Limited (ASX:WNX)

For further information, please contact:

Wellnex Life Limited (ASX:WNX)

George Karafotias

Chief Executive Officer

P: +61 3 8399 9419

E: george.k@wellnexlife.com.au



About Wellnex Life

Wellnex Life Limited (ASX: WNX) is a consumer healthcare business with a track record for developing, licensing, and marketing registered products and brands to customers in the growing healthcare market segment. Since listing in 2021, Wellnex Life has successfully launched a host of brands and products now ranged in major retailers in the healthcare market space, pharmacies and supermarkets included. Its distribution arrangements have seen Wellnex Life secure significant licensing arrangements with major pharmaceutical companies in Australia and globally that have given the company's registered products a distribution channel with a steadily increasing global geographic footprint.

Wellnex Life has more recently acquired leading Australian topical pain relief brand Pain Away. Its addition to Wellnex Life's product offering both compliments and accelerates the potential growth of the company's business operations. This transformational acquisition gives added impetus to Wellnex Life's financial growth and scale and reinforces its place as a major and respected participant in the growing healthcare market, both in Australia and overseas.

To learn more, please visit: www.wellnexlife.com.au/